Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
12:47pm, Monday, 06'th Jun 2022
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Why Is NuVasive (NUVA) Up 6.3% Since Last Earnings Report?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
02:26pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates
02:21pm, Thursday, 26'th May 2022 Zacks Investment Research
On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.
Change Healthcare (CHNG) Q4 Earnings Miss Estimates, Revenues Top
02:05pm, Thursday, 26'th May 2022 Zacks Investment Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
02:03pm, Thursday, 26'th May 2022 Zacks Investment Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
02:48pm, Wednesday, 25'th May 2022 Zacks Investment Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect a solid show by its segments and robust product portfolio.
Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
01:55pm, Wednesday, 25'th May 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv
If You Invested $1000 in Bio-Rad Laboratories 10 Years Ago, This Is How Much You'd Have Now
12:30pm, Wednesday, 25'th May 2022 Zacks Investment Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
11:33am, Wednesday, 25'th May 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv
15 stocks that have fallen at least 33% but by these measures are still standouts in their sectors
10:25am, Tuesday, 17'th May 2022 MarketWatch
Signature Bank, Nvidia, Salesforce and 12 other companies may be oversold, based on expectations for earnings and sales growth in 2023.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
02:31pm, Friday, 29'th Apr 2022 Zacks Investment Research
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
12:02pm, Friday, 29'th Apr 2022
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2022 Results - Earnings Call Transcript
11:03pm, Thursday, 28'th Apr 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2022 Earnings Conference Call April 28, 2022 6:00 PM ET Company Participants Ed Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Ch
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
09:45pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
